Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | CFTR | P13569 | 6/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1550570 | 0.86 | FAAH (0.53) | FAAHKMT2AKDM4EALDH1A1GLA | |
| SCHEMBL1550754 | 0.81 | P2RX7 (0.52) | CFTRKMT2AKDM4EALDH1A1GLA | |
| SCHEMBL1549789 | 0.81 | FAAH (0.56) | FAAHKMT2AKDM4EALDH1A1GLA | |
| SCHEMBL1921426 | 0.79 | FAAH (0.54) | FAAHKMT2AKDM4EALDH1A1GLA | |
| SCHEMBL30104821 | 0.79 | FAAH (0.54) | FAAHKMT2AMEN1NPC1RAB9A | |
| SCHEMBL11982568 | 0.79 | FAAH (0.54) | FAAHKMT2AKDM4EALDH1A1GLA | |
| SCHEMBL3932572 | 0.79 | FAAH (0.54) | FAAHKMT2AKDM4EALDH1A1GLA | |
| SCHEMBL14272176 | 0.79 | FAAH (0.54) | FAAHKMT2AMEN1NPC1RAB9A | |
| SCHEMBL14861236 | 0.76 | MEN1 (0.58) | FAAHKMT2AKDM4EGAAHPGD | |
| SCHEMBL5775681 | 0.76 | FAAH (0.51) | FAAHKMT2AKDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242124-B2 | Diketopiperidine derivatives as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242124-B2 | Diketopiperidine derivatives as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242124-B2 | Diketopiperidine derivatives as HIV attachment inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2313408-B1 | DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2313408-B1 | DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2313408-A1 | DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20090325985-A1 | Diketopiperidine Derivatives as HIV Attachment Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-31 | — | — | US | disclosed |
| US-20090325985-A1 | Diketopiperidine Derivatives as HIV Attachment Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-31 | — | — | US | disclosed |
| US-20090325985-A1 | Diketopiperidine Derivatives as HIV Attachment Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-31 | — | — | US | disclosed |
| WO-2009158396-A1 | DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158396-A1 | DIKETOPIPERIDINE DERIVATIVES AS HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325985-A1 | Diketopiperidine Derivatives as HIV Attachment Inhibitors | SAMHD1, CD4, DNPEP | FAAH 2134/4885CFTR 3770/4885MCL1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.